Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

Summary

CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms consisting of an open-label solriamfetol treatment period and a randomized, double-blind treatment period.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 65 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Axsome Therapeutics, Inc.

Last updated on ClinicalTrials.gov

October 13, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites